title: Aprepitant and fosaprepitant use in children and adolescents at an academic medical center.
abstract: OBJECTIVE
  To describe the use of aprepitant and fosaprepitant, a neurokinin 1 (NK-1) receptor inhibitor, in children and adolescents at a large academic medical center, for the prevention and management of chemotherapy-induced nausea and vomiting (CINV).
  
  
  METHODS
  A retrospective chart review was conducted using an electronic medical record system to evaluate the use of aprepitant and fosaprepitant in all pediatric patients that were discharged from a single academic medical center between February 25, 2009 and May 25, 2012.
  
  
  RESULTS
  Twenty-six patients were included in this review and received a total of 287 doses over the span of 114 cycles. Mean age was 10.1 years, with a range of 11 months to 17 years old. In 16 of 26 patients, aprepitant was used as the primary prophylaxis. Of those patients who received primary prophylaxis, 6 of 16 received it for highly emetogenic chemotherapy, and 10 of 16 received it for moderately emetogenic chemotherapy. Intravenous fosaprepitant was used in 7 of 26 patients, ages 13 to 17 (median 14) years old. No adverse effects attributable to aprepitant were reported.
  
  
  CONCLUSIONS
  Use of aprepitant and fosaprepitant in pediatric patients appeared to be well tolerated. No currently published reports data using aprepitant in a patient younger than 32 months old, whereas we reported its use in patients as young as 11 months old.
authors.affiliation: Department of Clinical Pharmacy, West Virginia University Healthcare, Morgantown, West Virginia ; Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, Mary Babb Randolph Cancer Center, West Virginia University Healthcare, Morgantown, West Virginia.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Shillingburg
authors.affiliation: Department of Clinical Pharmacy, West Virginia University Healthcare, Morgantown, West Virginia.
authors.forename: Lisa
authors.initials: L
authors.lastname: Biondo
keywords: antiemetics; aprepitant; nausea; vomiting